Cidara Therapeutics Unveils Promising Data on CD388 at ID Week
Cidara Therapeutics to Showcase Late-Breaking Data at ID Week
Cidara Therapeutics, Inc. (Nasdaq: CDTX), a pioneering biotechnology firm located in San Diego, is thrilled to announce a significant moment in its journey to combat influenza. The company will be sharing groundbreaking late-breaking Phase 2 clinical trial data on its antiviral influenza candidate, CD388, at the esteemed ID Week 2025 conference, set to unfold from October 19 to 22.
Insightful Presentation Details
At the event, the lead presenter, Dr. James Alexander, MD, MPH, FIDSA, will take the stage to discuss the findings of a randomized, placebo-controlled trial designed to evaluate the safety and efficacy of CD388. This innovative drug, a drug-Fc-conjugate, aims to prevent illness caused by both Influenza A and B among healthy, unvaccinated participants.
Key Presentation Details
Here’s a quick look at the presentation specifics:
- Title: A Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of CD388 for Prevention of Illness due to Influenza A and B
- Presenter: Dr. James Alexander
- Session: Extra, Extra! New Info on Treating and Preventing RSV and Influenza
- Location: B401-B402
- Date and Time: Monday, October 20, 2025, from 3:15 PM to 4:30 PM ET
About CD388 and Its Development
CD388 represents a promising route forward in the pursuit of effective influenza prevention. Built upon the foundation of Cidara’s proprietary Cloudbreak platform, this long-acting antiviral has the potential to provide universal seasonal and pandemic influenza protection with a single administration. By directly inhibiting the replication of the virus, CD388 could transform vaccine logistics for public health and provide a critical tool in controlling influenza outbreaks.
Fast Track Designation
In recognition of its potential impact, CD388 was granted Fast Track Designation by the FDA in a notable step forward for Cidara. This designation is designed to expedite the review process of drugs that fill an unmet need and has significant importance for therapies that can potentially save lives.
Recent Milestones for Cidara Therapeutics
The excitement surrounding CD388 isn't just theoretical. In June, Cidara announced promising top-line results from its Phase 2b NAVIGATE trial. The results underscore the safety and efficacy of CD388, marking a pivotal point in its developmental timeline.
Upcoming Phase 3 Trial Initiation
In addition to the promising Phase 2 results, Cidara commenced its Phase 3 ANCHOR trial in September to further evaluate the efficacy of CD388. This trial aims to extend its research further, aiming for comprehensive results that could lead to widespread use.
Connecting with Cidara Therapeutics
Cidara remains at the forefront of influenza research, with an ongoing commitment to innovation and patient health. By leveraging its unique Cloudbreak platform, the company continues to explore new avenues in drug development, with CD388 being a key focus. For more insights, potential investors and interested parties can connect with the company through its website.
Contact Information
For any inquiries regarding CD388 or the recent developments in their clinical trials, individuals can reach out to:
Investor Contact:
Brian Ritchie
LifeSci Advisors
(212) 915-2578
britchie@lifesciadvisors.com
Media Contact:
Michael Fitzhugh
LifeSci Communications
(628) 234-3889
mfitzhugh@lifescicomms.com
Frequently Asked Questions
What is CD388?
CD388 is a long-acting antiviral candidate developed by Cidara Therapeutics to prevent illness caused by Influenza A and B.
What makes the upcoming presentation significant?
The presentation will showcase late-breaking Phase 2 clinical data, which could provide insights into the effectiveness of CD388 against influenza.
How does the Fast Track Designation affect CD388?
This designation enhances the review process by the FDA, potentially leading to faster availability for patients if proven effective.
What are the expected outcomes of the ongoing Phase 3 trial?
The Phase 3 ANCHOR trial aims to further validate CD388's efficacy and safety, which could expedite its path to market.
How can I get more information about Cidara Therapeutics?
For more information, you can visit Cidara Therapeutics' official website for the latest updates and news regarding their clinical trials.
About The Author
Contact Logan Wright privately here. Or send an email with ATTN: Logan Wright as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.